TapewireFind a company

person · Reporting owner

Brainard Diana

Disclosed activity across 2 companies

Tapewire entity
74782
SEC CIK
0001818070

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Kalaris Therapeutics, Inc.ALVR · Entity 6805Director · Chief Executive OfficerNovember 19, 2024November 20, 2024
NEKTAR THERAPEUTICSNKTR · Entity 4364DirectorSeptember 23, 2026September 26, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Kalaris Therapeutics, Inc.

Report date November 19, 2024 · Filed November 20, 2024

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect723,363 Reported balance After 2024-11-19 transaction · row 1
1 source row

Row 1 · 2024-11-19 · Sale · Disposed 8,706 · Balance 723,363

F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

NEKTAR THERAPEUTICS

Report date September 23, 2026 · Filed September 26, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect3,904 Reported balance After 2026-09-23 transaction · row 1 Account or security details depend on footnotes; rows are not merged.
1 source row

Row 1 · 2026-09-23 · Grant · Acquired 2,000 · Balance 3,904

F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.

F2: This RSU award vests in full, one year following September 23, 2026.

F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.

Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $57.66 · Expires 2034-09-22Direct4,000 Reported balance After 2026-09-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2026-09-23 · Grant · Acquired 4,000 · Balance 4,000

F4: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.

F2: This RSU award vests in full, one year following September 23, 2026.

F3: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.

F4: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 23, 2026 Filed Sep 26, 2026 00:20 UTC NEKTAR THERAPEUTICS NKTR · Entity 4364 GrantStock Option · Derivative 4,000 $0.00 Strike: $57.66 $0.00
Disclosure

SEC source: 0001193125-26-403099 · ownership.xml · derivative · entry 2

Brainard Diana · CIK 0001818070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock · 4,000 shares

Expires 2034-09-22

F4 · derivative.exercise_date: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 23, 2026.

Read SEC document
September 23, 2026 Filed Sep 26, 2026 00:20 UTC NEKTAR THERAPEUTICS NKTR · Entity 4364 GrantCommon Stock 2,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-403099 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,904

F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.

F2 · deemedExecutionDate: This RSU award vests in full, one year following September 23, 2026.

F3 · balance_after: On June 8, 2025, the Issuer effected a one-for-fifteen reverse stock split of its common stock (the "Reverse Stock Split"). All amounts of securities listed herein have been adjusted to reflect the effect of the Reverse Stock Split.

Read SEC document
September 30, 2025 Filed Oct 1, 2025 23:50 UTC NEKTAR THERAPEUTICS NKTR · Entity 4364 GrantStock Option · Derivative 8,000 $0.00 Strike: $56.90 $0.00
Disclosure

SEC source: 0001193125-25-227233 · ownership.xml · derivative · entry 1

Brainard Diana · CIK 0001818070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,000

Underlying: Common Stock · 8,000 shares

Expires 2033-09-29

F1 · derivative.exercise_date: This stock option vests in substantially equal monthly installments over the one-year period beginning on September 30, 2025.

Read SEC document
November 19, 2024 Filed Nov 20, 2024 16:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 8,706 $0.55 $4,775.24
Disclosure

SEC source: 0000950170-24-129257 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 723,363

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.545 to $0.572. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
November 05, 2024 Filed Nov 6, 2024 16:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 10,609 $0.86 $9,175.72
Disclosure

SEC source: 0000950170-24-122336 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 732,069

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.856 to $0.9151. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
October 21, 2024 Filed Oct 23, 2024 16:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 9,752 $0.78 $7,596.81
Disclosure

SEC source: 0000950170-24-116645 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 742,678

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7544 to $0.7964. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
October 03, 2024 Filed Oct 4, 2024 16:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 1,493 $0.81 $1,216.50
Disclosure

SEC source: 0000950170-24-112912 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 752,430

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

Read SEC document
September 18, 2024 Filed Jan 18, 2025 01:32 UTC NEKTAR THERAPEUTICS NKTR · Entity 4364 GrantStock Option · Derivative 120,000 $0.00 Strike: $1.26 $0.00
Disclosure

SEC source: 0000950170-25-006883 · ownership.xml · derivative · entry 1

Brainard Diana · CIK 0001818070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,000

Underlying: Common Stock · 120,000 shares

Expires 2032-09-17

F1 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 18, 2024.

Read SEC document
August 20, 2024 Filed Aug 22, 2024 16:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 5,390 $0.74 $3,995.61
Disclosure

SEC source: 0000950170-24-099846 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 753,923

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7384 to $0.745. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
August 19, 2024 Filed Aug 20, 2024 16:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 3,091 $0.76 $2,347.61
Disclosure

SEC source: 0000950170-24-099102 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 759,313

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7373 to $0.7736. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
August 05, 2024 Filed Aug 7, 2024 16:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 10,847 $0.73 $7,970.38
Disclosure

SEC source: 0000950170-24-092807 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 762,404

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.73 to $0.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
July 19, 2024 Filed Jul 23, 2024 16:28 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 9,731 $0.75 $7,299.22
Disclosure

SEC source: 0000950170-24-085669 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 773,251

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7343 to $0.7925. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
July 02, 2024 Filed Jul 3, 2024 16:11 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 1,489 $0.72 $1,072.08
Disclosure

SEC source: 0000950170-24-081511 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 782,982

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

Read SEC document
May 21, 2024 Filed May 23, 2024 17:24 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 5,149 $0.79 $4,079.55
Disclosure

SEC source: 0000950170-24-064052 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 784,471

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7899 to $0.7994. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 17, 2024 Filed May 21, 2024 16:35 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 3,075 $0.75 $2,304.10
Disclosure

SEC source: 0000950170-24-062982 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 789,620

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.74 to $0.7615. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
May 03, 2024 Filed May 7, 2024 16:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 10,240 $0.80 $8,151.04
Disclosure

SEC source: 0000950170-24-054512 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 792,695

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7801 to $0.8098. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
April 19, 2024 Filed Apr 23, 2024 16:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 9,601 $0.75 $7,206.51
Disclosure

SEC source: 0000950170-24-046908 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 802,935

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7460 to $0.7562. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
April 02, 2024 Filed Apr 4, 2024 16:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 1,533 $0.77 $1,183.48
Disclosure

SEC source: 0000950170-24-041810 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 812,536

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7513 to $0.7801. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
February 21, 2024 Filed Feb 22, 2024 16:18 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 5,155 $0.71 $3,650.26
Disclosure

SEC source: 0000950170-24-018785 · ownership.xml · nonDerivative · entry 2

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 814,069

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.7002 to $0.7098. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
February 20, 2024 Filed Feb 22, 2024 16:18 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 3,097 $0.70 $2,153.03
Disclosure

SEC source: 0000950170-24-018785 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 819,224

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6832 to $0.7150. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
February 05, 2024 Filed Feb 6, 2024 16:38 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 41,421 $0.67 $27,752.07
Disclosure

SEC source: 0000950170-24-011769 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 822,321

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.66 to $0.6914. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
January 23, 2024 Filed Jan 25, 2024 16:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 9,500 $0.67 $6,368.80
Disclosure

SEC source: 0000950170-24-007406 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 863,742

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $0.6683 to $0.6794. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
January 04, 2024 Filed Jan 8, 2024 16:15 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 1,664 $0.64 $1,063.30
Disclosure

SEC source: 0000950170-24-002935 · ownership.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 873,242

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

Read SEC document
November 20, 2023 Filed Nov 21, 2023 17:00 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 4,382 $1.69 $7,407.77
Disclosure

SEC source: 0001209191-23-056313 · doc4.xml · nonDerivative · entry 2

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 874,906

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.69 to $1.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
November 17, 2023 Filed Nov 21, 2023 17:00 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 2,689 $1.63 $4,386.03
Disclosure

SEC source: 0001209191-23-056313 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 879,288

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.61 to $1.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
October 19, 2023 Filed Oct 23, 2023 17:00 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 8,581 $1.58 $13,557.98
Disclosure

SEC source: 0001209191-23-053349 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 881,977

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

Read SEC document
October 03, 2023 Filed Oct 5, 2023 17:00 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 1,325 $1.98 $2,618.60
Disclosure

SEC source: 0001209191-23-052229 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 890,558

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $1.95 to $2.03. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
September 19, 2023 Filed Sep 21, 2023 00:07 UTC NEKTAR THERAPEUTICS NKTR · Entity 4364 GrantStock Option · Derivative 85,000 $0.00 Strike: $0.68 $0.00
Disclosure

SEC source: 0001209191-23-050221 · doc4.xml · derivative · entry 1

Brainard Diana · CIK 0001818070 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Common Stock · 85,000 shares

Expires 2031-09-18

F1 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 19, 2023.

Read SEC document
August 18, 2023 Filed Aug 21, 2023 17:00 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 4,055 $2.79 $11,312.64
Disclosure

SEC source: 0001209191-23-046732 · doc4.xml · nonDerivative · entry 2

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 891,883

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.77 to $2.81. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
August 17, 2023 Filed Aug 21, 2023 17:00 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 11,361 $2.50 $28,351.38
Disclosure

SEC source: 0001209191-23-046732 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 895,938

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.45 to $2.56. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
July 19, 2023 Filed Jul 21, 2023 17:00 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 8,342 $3.56 $29,710.03
Disclosure

SEC source: 0001209191-23-043121 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 907,299

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.53 to $3.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
July 05, 2023 Filed Jul 6, 2023 17:00 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 5,275 $3.05 $16,062.90
Disclosure

SEC source: 0001209191-23-041583 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 915,641

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.96 to $3.15. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · balance_after: Includes 4,288 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on June 30, 2023.

Read SEC document
May 18, 2023 Filed May 19, 2023 17:00 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 4,536 $4.21 $19,114.70
Disclosure

SEC source: 0001209191-23-031074 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 916,628

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.04 to $4.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
April 19, 2023 Filed Apr 21, 2023 16:05 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 8,408 $3.71 $31,182.75
Disclosure

SEC source: 0001209191-23-025114 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 921,164

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.64 to $3.84. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
February 21, 2023 Filed Feb 23, 2023 17:00 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 5,122 $6.63 $33,935.30
Disclosure

SEC source: 0001209191-23-012250 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 929,572

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $6.54 to $6.73. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
February 02, 2023 Filed Feb 3, 2023 17:00 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 GrantStock Option (Right to Buy) · Derivative 617,500 $0.00 Strike: $6.65 $0.00
Disclosure

SEC source: 0001209191-23-006988 · doc4.xml · derivative · entry 2

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,836,875

Underlying: Common Stock · 617,500 shares

Expires 2033-02-02

F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter.

Read SEC document
February 02, 2023 Filed Feb 3, 2023 17:00 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 GrantCommon Stock 332,500 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-006988 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 934,964

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on February 2, 2024, with the remainder vesting in twelve equal quarterly installments thereafter.

Read SEC document
January 19, 2023 Filed Jan 23, 2023 19:00 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 34,435 $5.08 $174,850.60
Disclosure

SEC source: 0001209191-23-004499 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 601,607

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.94 to $5.19. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · balance_after: Includes 3,009 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on December 30, 2022.

Read SEC document
November 18, 2022 Filed Nov 21, 2022 17:47 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 4,515 $7.27 $32,810.05
Disclosure

SEC source: 0000899243-22-036553 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 633,033

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.23 to $7.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
September 16, 2022 Filed Sep 21, 2022 00:43 UTC NEKTAR THERAPEUTICS NKTR · Entity 4364 GrantStock Option · Derivative 20,400 $0.00 Strike: $3.47 $0.00
Disclosure

SEC source: 0001209191-22-050809 · doc4.xml · derivative · entry 2

Brainard Diana · CIK 0001818070 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,400

Underlying: Common Stock · 20,400 shares

Expires 2030-09-15

F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the one-year period beginning on September 16, 2022.

Read SEC document
September 16, 2022 Filed Sep 21, 2022 00:43 UTC NEKTAR THERAPEUTICS NKTR · Entity 4364 GrantCommon Stock 10,200 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-050809 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,560

F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.

F2 · deemedExecutionDate: This RSU award vests in full, one year following September 16, 2022.

Read SEC document
August 18, 2022 Filed Aug 19, 2022 16:05 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 4,564 $7.76 $35,428.51
Disclosure

SEC source: 0000899243-22-029271 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 637,548

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $7.67 to $7.86. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
August 16, 2022 Filed Aug 17, 2022 17:59 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 GrantCommon Stock 100,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-029046 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 642,112

F1 · shares: The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on August 16, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

Read SEC document
July 01, 2022 Filed Jul 6, 2022 07:30 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 GrantStock Option (Right to Buy) · Derivative 89,375 $0.00 Strike: $4.13 $0.00
Disclosure

SEC source: 0000899243-22-025231 · doc4.xml · derivative · entry 2

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,375

Underlying: Common Stock · 89,375 shares

Expires 2032-07-01

F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

Read SEC document
July 01, 2022 Filed Jul 6, 2022 07:30 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 GrantCommon Stock 48,125 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-025231 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 542,112

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

F2 · balance_after: Includes 1,822 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on June 30, 2022.

Read SEC document
May 18, 2022 Filed May 23, 2022 16:44 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 SaleCommon Stock 29,135 $4.33 $126,256.52
Disclosure

SEC source: 0000899243-22-019216 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 492,165

F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.19 to $4.63. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Read SEC document
January 18, 2022 Filed Apr 4, 2022 16:23 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 GrantStock Option (Right to Buy) · Derivative 585,000 $0.00 Strike: $9.15 $0.00
Disclosure

SEC source: 0000899243-22-013332 · doc4.xml · derivative · entry 2

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 585,000

Underlying: Common Stock · 585,000 shares

Expires 2032-01-18

F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

Read SEC document
January 18, 2022 Filed Apr 4, 2022 16:23 UTC Kalaris Therapeutics, Inc. ALVR · Entity 6805 GrantCommon Stock 315,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-22-013332 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 521,300

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

Read SEC document
November 11, 2021 Filed Nov 15, 2021 22:08 UTC NEKTAR THERAPEUTICS NKTR · Entity 4364 GrantStock Option · Derivative 36,720 $0.00 Strike: $13.55 $0.00
Disclosure

SEC source: 0001209191-21-064508 · doc4.xml · derivative · entry 2

Brainard Diana · CIK 0001818070 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,720

Underlying: Common Stock · 36,720 shares

Expires 2029-11-10

F3 · derivative.exercise_date: This stock option vests in equal monthly installments over the three-year period beginning on November 11, 2021.

Read SEC document
November 11, 2021 Filed Nov 15, 2021 22:08 UTC NEKTAR THERAPEUTICS NKTR · Entity 4364 GrantCommon Stock 18,360 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-064508 · doc4.xml · nonDerivative · entry 1

Brainard Diana · CIK 0001818070 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,360

F1 · security: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.

F2 · deemedExecutionDate: This RSU award vests over three years in equal annual installments beginning on November 11, 2021.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.